avexitide
Peptide Target: GLP-1 receptor
Amylyx Pharmaceuticals
Most recent annual filing: 2026-03-03
- Shih securities class action FDASep 10, 2026Shih securities class action FDA, Sep 10, 2026, routine
- RELYVRIO litigation FDA approvalSep 10, 2026RELYVRIO litigation FDA approval, Sep 10, 2026, routine
- AMX0318 IND filing2027AMX0318 IND filing, 2027, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (5 active programs)
sodium phenylbutyrate and taurursodiol
AMX0035AMX0114
Nucleic Acid Target: calpain-2, CAPN2
AMX0318
Peptide Target: GLP-1 receptor
Discontinued (1)
- AMX0035 — Progressive Supranuclear Palsy · discontinued after discontinuation of AMX0035 for PSP
Biotech Distilled coverage (7)
- 2026-08-20 UPDATE: Amylyx Pharmaceuticals (AMLX) - The $500 Million Vote of Confidence 🔒 Paid
- 2026-08-19 UPDATE: Amylyx Pharmaceuticals (AMLX) - The Coin Landed Heads 🔒 Paid
- 2026-08-17 UPDATE: Amylyx Pharmaceuticals (AMLX) - The Alarm Goes Off Tomorrow 🔒 Paid
- 2026-08-07 UPDATE: Amylyx Pharmaceuticals (AMLX) - The Binary Has a Date 🔒 Paid
- 2026-05-08 UPDATE: Amylyx Pharmaceuticals (AMLX) — The Quiet Tells Before the Binary 🔒 Paid
- 2026-03-28 UPDATE: Amylyx Pharmaceuticals (AMLX) - The Clock Starts Now 🔒 Paid
- 2026-03-11 Amylyx Pharmacueticals (AMLX) - Scientific Deep Dive for Avexitide and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.